High-mobility group box 1 and cancer - PubMed
Review
High-mobility group box 1 and cancer
Daolin Tang et al. Biochim Biophys Acta. 2010 Jan-Feb.
Abstract
High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival. Overexpression of HMGB1 is associated with each of the hallmarks of cancer including unlimited replicative potential, ability to develop blood vessels (angiogenesis), evasion of programmed cell death (apoptosis), self-sufficiency in growth signals, insensitivity to inhibitors of growth, inflammation, tissue invasion and metastasis. Our studies and those of our colleagues suggest that HMGB1 is central to cancer (abnormal wound healing) and many of the findings in normal wound healing as well. Here, we focus on the role of HMGB1 in cancer, the mechanisms by which it contributes to carcinogenesis, and therapeutic strategies based on targeting HMGB1.
Copyright 2009 Elsevier B.V. All rights reserved.
Figures

The high-mobility group box 1 protein (HMGB1) is present in almost all metazoans and plants. The expression of HMGB1 is regulated by transcription factors including p53, c-Myc, and KLF4 in individual cell types. As a DNA chaperone, HMGB1 participates in DNA replication, recombination, transcription and repair. HMGB1 also been interacts with and enhances the activities of a number of transcription factors implicated in cancer development, including p53, p73, the retinoblastoma protein (RB), members of the Rel/NF-κB family, and nuclear hormone receptors including the estrogen receptor (ER). Cytosolic HMGB1 promotes autophagy and, in particular, mitophagy. HMGB1 is passively released from necrotic cells and is actively secreted by inflammatory cells, binding with high affinity to several receptors including the receptor for advanced glycation end products (RAGE), Toll-like receptors (TLR)-2, TLR-4, TLR-9, and, as a negative signaling molecule, CD24, mediating the response to infection, immunity, autoimmunity, chemotaxis, cell proliferation and tissue regeneration.

In cancer, overexpression of HMGB1 is associated with each of the hallmarks of cancer including unlimited replicative potential, ability to develop blood vessels (angiogenesis), evasion of programmed cell death (apoptosis), self-sufficiency in growth signals, insensitivity to inhibitors of growth, inflammation, tissue invasion and metastasis.
Similar articles
-
Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter?
Seidu RA, Wu M, Su Z, Xu H. Seidu RA, et al. Oncol Rev. 2017 Mar 3;11(1):325. doi: 10.4081/oncol.2017.325. eCollection 2017 Mar 3. Oncol Rev. 2017. PMID: 28382190 Free PMC article. Review.
-
Masquerader: high mobility group box-1 and cancer.
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Ellerman JE, et al. Clin Cancer Res. 2007 May 15;13(10):2836-48. doi: 10.1158/1078-0432.CCR-06-1953. Clin Cancer Res. 2007. PMID: 17504981 Review.
-
HMGB1 in cancer: good, bad, or both?
Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. Kang R, et al. Clin Cancer Res. 2013 Aug 1;19(15):4046-57. doi: 10.1158/1078-0432.CCR-13-0495. Epub 2013 May 30. Clin Cancer Res. 2013. PMID: 23723299 Free PMC article. Review.
-
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523
-
Huang M, Geng Y, Deng Q, Li R, Shao X, Zhang Z, Xu W, Wu Y, Ma Q. Huang M, et al. Int J Oncol. 2018 Oct;53(4):1481-1492. doi: 10.3892/ijo.2018.4502. Epub 2018 Jul 25. Int J Oncol. 2018. PMID: 30066846 Free PMC article.
Cited by
-
HMGB1: The Central Cytokine for All Lymphoid Cells.
Li G, Liang X, Lotze MT. Li G, et al. Front Immunol. 2013 Mar 20;4:68. doi: 10.3389/fimmu.2013.00068. eCollection 2013. Front Immunol. 2013. PMID: 23519706 Free PMC article.
-
Novel chemokine-like activities of histones in tumor metastasis.
Chen R, Xie Y, Zhong X, Fu Y, Huang Y, Zhen Y, Pan P, Wang H, Bartlett DL, Billiar TR, Lotze MT, Zeh HJ 3rd, Fan XG, Tang D, Kang R. Chen R, et al. Oncotarget. 2016 Sep 20;7(38):61728-61740. doi: 10.18632/oncotarget.11226. Oncotarget. 2016. PMID: 27623211 Free PMC article.
-
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.
Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R. Exner R, et al. Cancer Med. 2016 Sep;5(9):2350-8. doi: 10.1002/cam4.827. Epub 2016 Jul 25. Cancer Med. 2016. PMID: 27457217 Free PMC article.
-
Hindi N, Carrillo-García J, Blanco-Alcaina E, Renshaw M, Luna P, Durán J, Jiménez N, Sancho P, Ramos R, Moura DS, Martín-Broto J. Hindi N, et al. Int J Mol Sci. 2023 Jan 3;24(1):856. doi: 10.3390/ijms24010856. Int J Mol Sci. 2023. PMID: 36614297 Free PMC article.
-
Chai W, Ye F, Zeng L, Li Y, Yang L. Chai W, et al. J Exp Clin Cancer Res. 2019 Jul 22;38(1):325. doi: 10.1186/s13046-019-1328-3. J Exp Clin Cancer Res. 2019. PMID: 31331356 Free PMC article.
References
-
- Goodwin GH, Johns EW. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol. 1977;16:257–267. - PubMed
-
- Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–342. - PubMed
-
- Dong XD, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ., 3rd High Mobility Group Box I (HMGB1) Release From Tumor Cells After Treatment: Implications for Development of Targeted Chemoimmunotherapy. J Immunother (1997) 2007;30:596–606. - PubMed
-
- Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13:2836–2848. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources